Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
St8 Micellar/Niosomal Vesicular Nanoformulation for Delivery of Naproxen in Cancer Cells: Physicochemical Characterization and Cytotoxicity Evaluation Publisher



Erfanimoghadam V1, 2 ; Aghaei M3 ; Soltani A3 ; Abdolahi N3 ; Ravaghi A3 ; Cordani M4 ; Shirvani S3 ; Rad SM3 ; Balakheyli H3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran
  2. 2. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran
  3. 3. Golestan Rheumatology Research Center, Golestan University of Medical Science, Gorgan, Iran
  4. 4. Institute for Advanced Studies in Nanoscience (IMDEA Nanociencia), Madrid, Spain

Source: Journal of Molecular Structure Published:2020


Abstract

Naproxen (NPX) is a non-steroidal anti-inflammatory drug (NSAID) used against a variety of diseases, including autoimmune disorders and chronic inflammations. However, low water solubility limits its therapeutic efficacy and novel nanoformulations are required to bypass its poor bioavailability to reach its therapeutic effect. The purpose of the study was to investigate the role of the nanoformulation of biocompatible molecules; Squalene (S) and Tween 80 (T8) Micellar/Niosomal Vesicles (ST8MNV) prepared, by thin-film hydration method and their potential as a drug delivery system for NPX. The percentage of encapsulation efficiency was calculated to be 99.5 ± 0.2% for 5% of NPX weight in total ingredients of micellar/niosomal vesicles (w/w). The ST8MNV nanoformulation exhibited a slower rate of NPX release from the drug encapsulated over seven days, suggesting a stable complex of NPX. Finally, cell toxicity assay demonstrated that the half-maximal inhibitory concentrations (IC50) of NPX were drastically reduced by ST8MNV nanoformulation in MCF-7, A549, HeLa, and MDA-MB-231 cancer cell lines. Our data show this micellar/niosomal naproxen nanoformulation is a great candidate for the future in vitro and in vivo studies for potential clinical anti-inflammatory and anticancer applications. © 2020 Elsevier B.V.
Related Docs
1. Optimized Doxycycline-Loaded Niosomal Formulation for Treatment of Infection-Associated Prostate Cancer: An In-Vitro Investigation, Journal of Drug Delivery Science and Technology (2020)
2. Niosomes: A Novel Targeted Drug Delivery System for Cancer, Medical Oncology (2022)
3. Niosomal Formulation for Antibacterial Applications, Journal of Drug Targeting (2022)
4. Cationic Vesicles for Efficient Shrna Transfection in the Mcf-7 Breast Cancer Cell Line, International Journal of Nanomedicine (2018)
5. Smart Mesoporous Silica Nanoparticles for Controlled-Release Drug Delivery, Nanotechnology Reviews (2016)
6. Preparation and Optimization of Ciprofloxacin Encapsulated Niosomes: A New Approach for Enhanced Antibacterial Activity, Biofilm Inhibition and Reduced Antibiotic Resistance in Ciprofloxacin-Resistant Methicillin-Resistance Staphylococcus Aureus, Bioorganic Chemistry (2020)
Experts (# of related papers)
Ronak Bakhtiari (1)